ClinicalTrials.gov
ClinicalTrials.gov Menu

The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03181191
Recruitment Status : Recruiting
First Posted : June 8, 2017
Last Update Posted : June 12, 2017
Sponsor:
Collaborator:
University of Copenhagen
Information provided by (Responsible Party):
Mille Baekdal Nielsen, University Hospital, Gentofte, Copenhagen

Brief Summary:
Delineation of the anatomical location, cellular origin and molecular basis of gut-derived glucagon secretion

Condition or disease Intervention/treatment Phase
Glucose Metabolism Disorders Other: Oral glucose tolerance test Not Applicable

Detailed Description:

Aim: to delineate the anatomical origin, the molecular structure and precursors, the regulation and the (patho-) physiological implications of gut-derived glucagon.

Eight totally pancreatectomised patients, eight type 2 diabetes patients and eight healthy controls (age 18-80, BMI <30) with normal kidney and liver parameters and hgb> 6.5 - will be included. The participants will each undergo one screening day and one study day including a gastroduodenoscopy. Multiple biopsies will be taken at several predefined locations in the upper gastrointestinal tract. These biopsies will be analysed with different techniques including immunohistochemical staining, quantitative polymerase chain reaction (qPCR-) analyses and more to search for glucagon. After the last biopsy has been collected, 50 g of glucose dissolved in 100 ml water is infused through the enteroscope into the most proximal part of the small intestine. Hereafter blood samples for glucagon and gut hormone analyses will be collected 15, 30 and 45 min after the glucose infusion.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion
Actual Study Start Date : April 27, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Glucagon

Arm Intervention/treatment
Active Comparator: Totally pancreatectomised patients
Oral glucose tolerance test and biopsies
Other: Oral glucose tolerance test
Oral glucose tolerance test and biopsies

Active Comparator: Type 2 diabetes patients
Oral glucose tolerance test and biopsies
Other: Oral glucose tolerance test
Oral glucose tolerance test and biopsies

Active Comparator: Healthy control subjects
Oral glucose tolerance test and biopsies
Other: Oral glucose tolerance test
Oral glucose tolerance test and biopsies




Primary Outcome Measures :
  1. gut-derived glucagon [ Time Frame: 1 year ]
    The primary objective is to investigate mucosal biopsies from specific regions of the upper gastrointestinal tract


Secondary Outcome Measures :
  1. Oral glucose tolerance test [ Time Frame: 45 minutes ]
    Glucose metabolism - hormones, insulin, glucagon, glp-1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • normal kidney function, normal liver function, normal hemoglobin levels

Exclusion Criteria:

  • diabetes type 1, first degree relatives with type 2 diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03181191


Contacts
Contact: Mille Baekdal, MD +45 26700782 mille.baekdal.nielsen@regionh.dk
Contact: Filip Knop, MD, PhD filipknop@dadlnet.dk

Locations
Denmark
Center for Diabetes Research Recruiting
Hellerup, Denmark, 2900
Contact: Mille Baekdal, MD    +45 26700782    mille.baekdal.nielsen@regionh.dk   
Contact: Filip Knop, MD, PhD       filipknop@dadlnet.dk   
Sponsors and Collaborators
Mille Baekdal Nielsen
University of Copenhagen
Investigators
Study Director: Filip Knop, MD, PhD University Hospital, Gentofte, Copenhagen

Responsible Party: Mille Baekdal Nielsen, MD, University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier: NCT03181191     History of Changes
Other Study ID Numbers: UHG-CFD-PX-BIOPSY
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: June 12, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Metabolic Diseases
Glucose Metabolism Disorders
Glucagon
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs